{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:46:39Z","timestamp":1789663599065,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.126245","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:49:14Z","timestamp":1725025754000},"page":"126245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59"],"prefix":"10.1016","volume":"42","author":[{"given":"Xin","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126245_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2024.126245_bb0010","series-title":"in Comprehensive Cervical Cancer Control: A Guide to Essential Practice (World Health Organization) Copyright \u00a9 World Health Organization 2014","year":"2014"},{"key":"10.1016\/j.vaccine.2024.126245_bb0015","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers - a brief historical account","volume":"384","author":"zur Hausen, H.","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"de Villiers","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0025","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/v7072802","article-title":"Human papillomaviruses; epithelial tropisms, and the development of neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126245_bb0030","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"D\u00fcrst","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2024.126245_bb0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4424","article-title":"Are 20 human papillomavirus types causing cervical cancer?","volume":"234","author":"Arbyn","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2018.04.003","article-title":"Towards quality and order in human papillomavirus research","volume":"519","author":"M\u00fchr","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"Roden","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2024.126245_bb0050","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0006-3495(91)82181-6","article-title":"Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction","volume":"60","author":"Baker","year":"1991","journal-title":"Biophys J"},{"key":"10.1016\/j.vaccine.2024.126245_bb0055","doi-asserted-by":"crossref","first-page":"31803","DOI":"10.1074\/jbc.M706380200","article-title":"Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies","volume":"282","author":"Bishop","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2024.126245_bb0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.str.2016.04.008","article-title":"The C-terminal arm of the human papillomavirus major capsid protein is immunogenic and involved in virus-host interaction","volume":"24","author":"Li","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.vaccine.2024.126245_bb0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1994.1649","article-title":"Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes","volume":"205","author":"Christensen","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00787-17","article-title":"Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus","volume":"8","author":"Li","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2024.126245_bb0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/JVI.72.2.959-964.1998","article-title":"In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16","volume":"72","author":"White","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.virol.2015.04.016","article-title":"Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization","volume":"483","author":"Guan","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0085","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0090","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/jvi.70.5.3298-3301.1996","article-title":"Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition","volume":"70","author":"Roden","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0095","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126245_bb0100","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126245_bb0105","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126245_bb0110","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cncr.29374","article-title":"FDA approves Gardasil 9 for more types of HPV","volume":"121","author":"Printz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2024.126245_bb0115","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.vaccine.2024.126245_bb0120","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1002\/jmv.27013","article-title":"Prevalence and genotype distribution of high-risk HPV infection among women in Beijing, China","volume":"93","author":"Zhu","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fcimb.2019.00059","article-title":"Changes in cervical human papillomavirus (HPV) prevalence at a youth Clinic in Stockholm, Sweden, a decade after the introduction of the HPV vaccine","volume":"9","author":"\u00c4hrlund-Richter","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2013.05.012","article-title":"Evolution of the papillomaviridae","volume":"445","author":"Van Doorslaer","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126245_bb0135","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes","volume":"22","author":"Mesher","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126245_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw300","article-title":"Evaluation of type replacement following HPV16\/18 vaccination: pooled analysis of two randomized trials","volume":"109","author":"Tota","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2024.126245_bb0145","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/aje\/kwu265","article-title":"Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination","volume":"180","author":"Safaeian","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0150","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1038\/s41467-018-07199-6","article-title":"Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126245_bb0155","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nmeth.1515","article-title":"Chemical synthesis of the mouse mitochondrial genome","volume":"7","author":"Gibson","year":"2010","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2024.126245_bb0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126245_bb0165","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2012.10.032","article-title":"Antigenic analysis of divergent genotypes human enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity","volume":"31","author":"Chen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126245_bb0170","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1016\/j.vaccine.2017.06.084","article-title":"Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine","volume":"35","author":"Gu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126245_bb0175","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1128\/JVI.77.15.8386-8393.2003","article-title":"Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16","volume":"77","author":"Varsani","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0180","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jmv.21124","article-title":"Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes","volume":"80","author":"Kondo","year":"2008","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0185","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0190","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","volume":"83","author":"Schellenbacher","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126245_bb0195","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1016\/j.vaccine.2019.05.011","article-title":"Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity","volume":"37","author":"Schellenbacher","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126245_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10051044","article-title":"RG1-VLP and other L2-based, broad-Spectrum HPV vaccine candidates","volume":"10","author":"Huber","year":"2021","journal-title":"J Clin Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:56:27Z","timestamp":1729014987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":40,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24009277"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126245","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126245"}}